Hybrid DNA/RNA CRISPR Guides for Specific Genome Cleavage

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

Existing CRISPR/Cas systems face issues with RNA-DNA hybrid structures, such as RNase A degradation and higher RNA-DNA mismatches, leading to inefficiencies and increased costs in RNA oligonucleotide synthesis, and lack specificity in target recognition.

Innovation Solution

A hybrid DNA/RNA polynucleotide system is introduced for Class 2 CRISPR systems, combining a targeting region of DNA with an activating region of RNA, which can be upstream or downstream, and interacting with Cas9 or Cpf1 proteins, forming structures like stem loops to enhance specificity and reduce off-target modifications.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If RNA-based CRISPR guide sequences are used, then the system can naturally hybridize with target DNA, but the RNA strand is susceptible to RNase A degradation and forms unstable RNA-DNA hybrids

Engineering Contradiction:
Improvestability of guide sequenceVSAvoidRNase A degradation
Core Design Contradiction:
ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent changes the chemical composition parameter of the guide sequence from RNA to DNA, creating a DNA-based CRISPR guide that is resistant to RNase A degradation while maintaining hybridization capability with target DNA sequences

Inventive Principle:
Principle #35Parameter changes

Solution Approach 2:

The patent creates a hybrid DNA-RNA system where the guide sequence is DNA and the target is DNA, forming a stable DNA-DNA hybrid that combines the stability of DNA with the sequence-specific recognition capabilities of the CRISPR system

Inventive Principle:
Principle #40Composite materials

2Ease of manufacture

If RNA guide sequences are used, then the CRISPR system can be implemented, but synthesis costs increase and robustness decreases

Engineering Contradiction:
Improvesynthesis cost and robustnessVSAvoidRNA oligonucleotide synthesis complexity
Core Design Contradiction:
Ease of manufactureVSQuantity of substance

Solution Approach 1:

The patent replaces expensive and fragile RNA oligonucleotides with cheaper and more robust DNA oligonucleotides as the guide sequence, reducing synthesis costs and improving handling robustness while maintaining functional equivalence

Inventive Principle:
Principle #27Cheap short-living objects (Disposable)

3Measurement precision

If RNA-based CRISPR systems are used, then target recognition can occur, but specificity is reduced due to higher RNA-DNA mismatch tolerance

Engineering Contradiction:
Improvetarget recognition specificityVSAvoidRNA-DNA mismatch tolerance
Core Design Contradiction:
Measurement precisionVSManufacturing precision

Solution Approach 1:

The patent changes the chemical nature of the guide sequence from RNA to DNA, which alters the hybridization properties and reduces tolerance for mismatches, thereby improving target recognition specificity and reducing off-target effects

Inventive Principle:
Principle #35Parameter changes

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The hybrid DNA/RNA polynucleotide system improves target specificity and reduces off-target effects, offering cost-effective and robust genome editing by preferentially cleaving at target sequences.

Implementation Method 1

a targeting region comprising deoxyribonucleic acid (DNA) and configured to hybridize with a target sequence in a nucleic acid

Methodology Applied
Scientific EffectHybridization:

Implementation Method 2

wherein the polynucleotide forms a complex with a site-directed polypeptide and wherein the target nucleic acid is cleaved

Methodology Applied
Scientific EffectEnzymatic cleavage: Enzyme

Data Source

PatentUS20250376700A1Crispr hybrid DNA/RNA polynucleotides and methods of use
Publication Date: 2025.12.11 CARIBOU BIOSCIENCES INC
  • US20250376700A1 patent drawing
  • US20250376700A1 patent drawing
  • US20250376700A1 patent drawing

AI summary

The present disclosure provides DNA-guided CRISPR systems; polynucleotides comprising DNA, RNA and mixtures thereof for use with CRISPR systems; and methods of use involving such polynucleotides and DNA-guided CRISPR systems.